Selection and concentration in pharmaceutical development operations
First written in FY2016. 26 of 28 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the interim consolidated accounting period.」
The Company states that there has been no material change in the current status or outlook of its management strategy and indicates that its policy of differentiation through selectivity and concentration in contract services remains in place. - FY2025-H1RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the interim consolidated accounting period. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2024ReframedAnnual report
「We provide a range of clinical trial services globally through a one-stop model, covering the clinical trial planning stage and all phases of clinical trials.」
Compared with the previous description of selecting and concentrating on specific services and stages, the stated scope of the strategy now covers global, one-stop services from clinical trial planning through all phases. - FY2024-Q3RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first nine months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2024-Q2RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first six months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2024-Q1RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first three months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2023-Q2RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first six months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2023-Q1RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first three months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2022-Q3RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first nine months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2022-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in the current status or outlook of its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2021-Q3RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first nine months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2021-Q2RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first six months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company states that there has been no material change in its management strategy and reaffirms its policy of differentiation through selectivity and concentration in contract services. - FY2021-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
There has been no material change in the policy of differentiating the Company from existing CROs through selectivity and concentration in contract services and pursuing the CDO model. - FY2020RestatedAnnual report
「To meet the requirements of the pharmaceutical companies described above, our group is differentiating itself from other companies in the industry by developing its core CRO business toward becoming a CDO specializing primarily in monitoring during Phase II and Phase III, the principal stages of clinical trials, together with related quality control and consulting services.」
The policy of differentiation through selectivity and concentration in specific clinical trial stages and contract services continues to be stated in the annual report. - FY2020-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of differentiation through selectivity and concentration in contract services has been reaffirmed without material change. - FY2020-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of differentiating the Company from existing CROs through selectivity and concentration in contract services has been reaffirmed without material change. - FY2019-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of differentiating the Company from existing CROs through selectivity and concentration in contract services has been reaffirmed without material change. - FY2019-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of differentiating the Company from existing CROs through selectivity and concentration in contract services has been reiterated without material change. - FY2019-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
There has been no material change in the policy of differentiating the Company from existing CROs through selectivity and concentration in contract services. - FY2018RestatedAnnual report
「Our group focuses on specific areas, contract services and clinical trial stages, and refers to a CRO with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies as a CDO (Contract Development Organization).」
The policy of pursuing a CDO through selectivity and concentration in specific areas, contract services and clinical trial stages remains in place. - FY2018-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
There has been no material change in the policy of differentiating the Company from existing CROs through selectivity and concentration in contract services. - FY2018-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major Japanese pharmaceutical companies.」
The Company states that there has been no material change in its policy of differentiation through selectivity and concentration in contract services. - FY2018-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of differentiating the Company from existing CROs through selectivity and concentration in contract services remains in place without material change. - FY2017RestatedAnnual report
「Going forward, we will focus on monitoring in Phase II and Phase III, the principal stages of clinical trials, as well as related quality control and consulting services. As a CRO capable of collecting highly reliable data at appropriate contract fees, we intend to meet customer expectations.」
The Company continues to select and concentrate on specific clinical trial stages and contract services, with monitoring, quality control and consulting at the core of its operations. - FY2017-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of using selectivity and concentration in contract services as a means of differentiation remains in place without material change. - FY2017-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major Japanese pharmaceutical companies.」
The policy of differentiation through selectivity and concentration in contract services remains in place. - FY2017-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of differentiation through selectivity and concentration in contract services remains in place without material change. - FY2016First statedAnnual report
「To this end, our group is pursuing a strategy of selecting and concentrating its management resources, focusing on specific pharmaceutical development services and stages.」
Rather than expanding the scope of services and clinical trial stages, the Company uses concentration on specific areas as a means of differentiation.